Foley Trasimene Acquisition Corp .: “There are so many of these things that it’s very difficult to follow and I don’t want you in them. I’m done with that era. I think we need to let these actions decrease … It’s too damn hard for investors. “
Platoon: “He had a great run and I’m moving on.”
Tellurian: “It’s a great $ 2 spec. I call it a call option. It’s almost a lottery ticket, but I don’t like to bet against it. [co-founder] Charif Souki “.
Palantir: “I don’t think it’s time to double … Don’t double until something has dropped significantly enough to change you [cost] the base.”
G1 Therapeutics: “These are stocks I never tell anyone, as long as they recognize that it’s speculative stock in their portfolio. It’s not like you own a Merck.”